Amivantamab, a new cancer jab developed by Johnson & Johnson, has yielded 'unprecedented' results in a major clinical trial involving 102 patients with advanced head and neck cancer across 11 countries. The trial revealed that over one-third of the participants experienced significant tumor shrinkage, with 15 patients achieving complete eradication of their tumors. This innovative treatment operates by targeting a specific protein that aids in tumor growth, effectively blocking a pathway that cancer cells exploit to resist therapy. Furthermore, it activates the body's immune system to help combat the disease. Remarkably, patients receiving amivantamab had a median survival of 12.5 months after beginning treatment, despite facing poor prognoses. One participant, Carl Walsh, expressed his satisfaction with the treatment's effectiveness. These promising results are set to be presented at the upcoming American Society of Clinical Oncology annual meeting in Chicago, and amivantamab is currently in approximately 60 other clinical trials for various cancer types, including lung, colorectal, brain, and gastric cancers.